Jazz Pharmaceuticals (JAZZ) Net Cash Flow Growth (3y) (2013 - 2026)
Jazz Pharmaceuticals (JAZZ) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,184.45 Bn | 68,184.17 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 474.39 Bn | 469.59 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.21 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 63.43 Bn | 63.43 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.49 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.08 Bn | 38.08 Bn | - | - |
| 10 | Jazz Pharmaceuticals | 15.78 Bn | 13.94 Bn | 934.80 Mn | 16.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.54% |
| Dec 31, 2025 | 20.95% |
| Sep 30, 2025 | 0.61% |
| Jun 30, 2025 | -71.13% |
| Mar 31, 2025 | -77.33% |
| Dec 31, 2024 | 65.04% |
| Sep 30, 2024 | 81.13% |
| Jun 30, 2024 | 58.41% |
| Mar 31, 2024 | -27.22% |
| Dec 31, 2023 | -18.80% |
| Sep 30, 2023 | 47.74% |
| Jun 30, 2023 | 10.88% |
| Mar 31, 2023 | 63.71% |
| Dec 31, 2022 | 30.72% |
| Sep 30, 2022 | -5.53% |
| Jun 30, 2022 | 35.62% |
| Mar 31, 2022 | -34.19% |
| Dec 31, 2021 | 25.16% |
| Sep 30, 2021 | -151.09% |
| Jun 30, 2021 | -247.25% |